# Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

> **NCT03703050** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 45 (actual)

## Conditions studied

- Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Nivolumab cohort 1
- **DRUG:** Nivolumab cohort 2

## Key facts

- **NCT ID:** NCT03703050
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-02
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03703050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03703050, "Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03703050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*